Ивашкин В. Т., Драпкина О. М., Клименков А. В. Новые методы борьбы с дислипидемией. Кардиоваскулярная терапия и профилактика. 2006;5(7):95-100.
1. Федеральная целевая программа "Профилактика и лечение артериальной гипертонии в Российской Федерации". Министерство здравоохранения Российской Федерации. www.programs-gov.ru
2. Амосова Е.Н. Атеросклероз: некоторые факты о холестерине/Ж практ врача -1996-5-34-8.
3. Аронов Д.М. Лечение и практика атеросклероза. -Москва: Триада-Х, 2000; 411с.
4. Жданов B.C., Вихерт А.М., Стернби Н.Г. Эволюция и патология атеросклероза у человека. -Москва: Триада-Х, 2002; 144с.
5. Зайчик А.Ш., Чурилов Л.П. Основы патохимии. -СПб: Элби, 2000; 688с.
6. Климов А.Н., Никуличева H.Г. Обмен липидов и липопротеидов и его нарушения. -Санкт-Петербург: Питер, 1999; 505с.
7. Hjermann I., Holme I., Velve В.К., Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the OSLO study group of a randomized trial in healthy men. Lancet 1981;II: 1303-10.
8. Parikh P., McDaniel M.C., Ashen M.D., et al. Diets and Cardiovascular Disease: An Evidence-Based Assessment. JACC 2005: 45: 1379-87
9. Hennekens C.H. Clinical and research challenges in risk factors for cardiovascular diseases. Eur Heart J. 2000:21:1917-21.
10. Thompson G.R., Holyer J., Waters D.D. Percentage change rather than plasma level of LDLcholesterol determines therapeutic response in coronary heart disease.Curr. Opinion Lipidol 1995, 6:386-8.
11. Thompson G.R. What targets should lipidmodulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis 1997, 131:15.
12. Smith S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006;113: 2363-72.
13. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
14. Eidelman R.S., Lamas G.A., Hennekens C.H. The New National Cholesterol Education Program Guidelines. Clinical Challenges for More Wdespread Therapy of Lipids to Treat and Prevent Coronary Heart Disease.Arch Intern Med 2002; 162:2033-6.
15. Waters D., Higginson L., Gladstone P., et al. Effects of monotherapy with an HMG CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Interventional Trial. Circulation 1994; 89(3):959-68.
16. Jones P., Kafonek S., Laurora I., et al. Comparative Dose Efficacy Study of Atorvastatin vs Simvastatin, Pravastatin, Lovastatin, Fluvastatin in patients with hypercholesterolemia (The CURVES study). Am J Cardiol 1998; 81: 582-7.
17. Аронов Д.М. Статины снижают смертность и улучшают течение атеросклеротических заболеваний./Cons Med 2001 1(10).
18. Law М. Plant sterol and stanol margarines and health. BMJ 2000;320:861-4
19. Miettinen Т.А., Puska P., Gylling H., et al. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995; 333:1308-12.
20. Peterson D.W. Effect of soybean sterols in the diet on plasma and liver cholesterol in chicks. Proc Soc Exp Biol Med 1951;78:143-7.
21. Sugano M., Morioka H., Ikeda I. A comparison of hypocholesterolemic activity of -sitosterol and -sitostanol in rats. J Nutr 1977;107:2011-9.
22. Gylling H., Radhakrishnan R., Miettinen Т.А. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine. Circulation 1997; 96: 4226-31
23. Gylling H., Miettinen Т.А. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia 1994; 37: 773-80
24. Best M.M., Duncan C.H., Van Loon E.J., Wathen J.D. Lowering of serum cholesterol by the administration of a plant sterol. Circulation 1954; 10: 201-6
25. Jones P.J.H., MacDougall D.E., Ntanios F., Vanstone C.A. Dietary phytosterols as cholesterol-lowering agents in humans. Can J Physiol Pharmacol 1997; 75: 217-27
26. Heinemann T., Kullak-Ublick A., Pietruck B., von Bergmann K. Mechanisms of action of plant sterols on inhibition of cholesterol absorption. Eur J Clin Pharmacol 1991; 40(suppl 1): 59S -63.
27. Heinemann T., Pietruck B., Kullak-Ublick G., Von Bergmann K. Comparison of sitosterol and sitostanol on inhibition of intestinal cholesterol absorption. Agents Actions Suppl 1988; 26: 117-22
28. Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. A controlled clinical trial. Acta Med. Scand;1966. 466 (Suppl.): 1-92.
29. Dayton S., Pearce M.L., Goldman H., et al. Controlled trial of a diet high in unsaturated fat for prevention of atherosclerotic complications. Lancetl968; 2: 1060-2.
30. Turpeinen O. Diet and coronary events. J Am Diet Assoc 1968; 52: 209-13.
31. Miettinen M., Turpeinen O., Karvonen M.J., et al. Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes. A twelve-year clinical trial in men and women. Lancet 1972; 2 (7782): 835-8.
32. Hallikainen M.A., Uusitupa M.I. Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of low-fat diet in hypercholesterolemic subjects. Am J Clin Nutr, 1999; 69 (3): 403-10.
33. Blair S.N., Capuzzi D.M., Gottlieb S.O., et al. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol. 2000;86:46-52.
34. de Lorgeril M., Salen P., Martin J.L., et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99: 779-85.
